İçeriğe geç
akaturk Akademik ölçüm

OpenAlex konusu

Peripheral Neuropathies and Disorders

Bu sayfa OpenAlex konu etiketine göre çalışmaları ve o konuda görünen akademisyenleri listeler. YÖKSİS temel alan / yan dal değildir.

OpenAlex 3.136 eser 63 yazar konusu

Çalışmalar

3.136 eser

  1. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    OBJECTIVE: To report the autoantigens of a new category of treatment-responsive paraneoplastic encephalitis. METHODS: Analysis of clinical features, neuropathological findings, tumors, and serum/cerebrospinal fluid antibodies using rat tissue, neuronal cultures, and HEK293 cells expressing subunits of the N-methyl-D-a…

  2. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. METHODS: In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dos…

  3. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    BACKGROUND: Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies. METHODS: We randomly a…

  4. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    BACKGROUND: Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies. METHODS: We randomly a…

  5. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  6. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  7. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  8. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  9. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  10. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  11. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    BACKGROUND: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known. METHODS: In two double-blind, do…

  12. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Importance: Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never usi…

Akademisyenler

63 akademisyen